Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas

Nature Genetics

Volumn 47, Issue 10, 2015, Pages 1187-1193

  Nault, Jean Charles ^a,b,c,d,e   Datta, Shalini ^a,b,c,d   Imbeaud, Sandrine ^a,b,c,d   Franconi, Andrea ^a,b,c,d   Mallet, Maxime ^a,b,c,d   Couchy, Gabrielle ^a,b,c,d   Letouzé, Eric ^a,b,c,d   Pilati, Camilla ^a,b,c,d   Verret, Benjamin ^a,b,c,d   Blanc, Jean Frédéric ^f,g,h   Balabaud, Charles ^g,h   Calderaro, Julien ^a,b,c,d,i   Laurent, Alexis ^i,j   Letexier, Mélanie ^k   Bioulac Sage, Paulette ^g,h,l   Calvo, Fabien ^a,b,c,d,m   Zucman Rossi, Jessica ^a,b,c,d,e  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g UMR 1053 ^*  (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j INSERM U955   (France)

^k IntegraGen   (France)

^l HÔPITAL PELLEGRIN   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 2; ADULT; ALCOHOL INTOLERANCE; ARTICLE; CANCER PATIENT; CCNA2 GENE; CCNE1 GENE; CONTROLLED STUDY; DNA VIRUS; FEMALE; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INSERTIONAL MUTAGENESIS; KMT2B GENE; LIVER CELL CARCINOMA; MALE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; TERT GENE; TNFSF10 GENE; DEPENDOPARVOVIRUS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MOLECULAR GENETICS; VIRUS DNA CELL DNA INTERACTION;

CCNE1 PROTEIN, HUMAN; CYCLIN A2; CYCLIN E; ONCOPROTEIN; TELOMERASE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CARCINOMA, HEPATOCELLULAR; CYCLIN A2; CYCLIN E; DEPENDOVIRUS; HUMANS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; ONCOGENE PROTEINS; TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIRUS INTEGRATION;

EID: 84942905508     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3389     Document Type: Article

References (49)

1. Forner A., Llovet J.M., & Bruix J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012
2. Fujimoto A., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012
3. Guichard C., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012
4. Nault J.C., et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013
5. Totoki Y., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014
6. Schulze K., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511 (2015
7. Sung W.K., et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765-769 (2012
8. Paterlini-Bréchot P., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22, 3911-3916 (2003
9. Nault J.C., et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983-1992 (2014
10. Pilati C., et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 25, 428-441 (2014
11. Atchison R.W., Casto B.C., & Hammon W.M. Adenovirus-associated defective virus particles. Science 149, 754-756 (1965
12. Smith R.H. Adeno-associated virus integration: virus versus vector. Gene Ther. 15, 817-822 (2008
13. Flotte T.R., & Berns K.I. Adeno-associated virus: a ubiquitous commensal of mammals. Hum. Gene Ther. 16, 401-407 (2005
14. Samulski R.J., et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10, 3941-3950 (1991
15. McAlister V.J., & Owens R.A. Preferential integration of adeno-associated virus type 2 into a polypyrimidine/polypurine-rich region within AAVS1. J. Virol. 81, 9718-9726 (2007
16. Kotin R.M., et al. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87, 2211-2215 (1990
17. Deshpande A., Sicinski P., & Hinds P.W. Cyclins and CDKs in development and cancer: a perspective. Oncogene 24, 2909-2915 (2005
18. Berasain C., et al. Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene 16, 1277-1288 (1998
19. Johnstone R.W., Frew A.J., & Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782-798 (2008
20. Ding D., et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet. 8, e1003065 (2012
21. Gonçalves M.A. Adeno-associated virus: from defective virus to effective vector. Virol. J. 2, 43 (2005
22. Neuveut C., Wei Y., & Buendia M.A. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 52, 594-604 (2010
23. Martin D., & Gutkind J.S. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27 (suppl. 2), S31-S42 (2008
24. Wang J., Chenivesse X., Henglein B., & Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343, 555-557 (1990
25. Haberman R.P., McCown T.J., & Samulski R.J. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J. Virol. 74, 8732-8739 (2000
26. Baudard M., et al. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum. Gene Ther. 7, 1309-1322 (1996
27. Moore P.S., & Chang Y. Why do viruses cause cancer?. Highlights of the first century of human tumour virology. Nat. Rev. Cancer 10, 878-889 (2010
28. Calcedo R., Vandenberghe L.H., Gao G., Lin J., & Wilson J.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381-390 (2009
29. Halbert C.L., et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum. Gene Ther. 17, 440-447 (2006
30. Nathwani A.C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011
31. Le Witt P.A., et al. AAV2-GAD gene therapy for advanced Parkinsons disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319 (2011
32. Donsante A., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007
33. Chandler R.J., et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870-880 (2015
34. Wang P.R., et al. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc. Natl. Acad. Sci. USA 109, 11264-11269 (2012
35. Bell P., et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol. Ther. 14, 34-44 (2006
36. Rosas L.E., et al. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol. Ther. 20, 2098-2110 (2012
37. Gnirke A., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009
38. Rebouissou S., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009
39. Li H., & Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010
40. Li H., et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009
41. Thorvaldsdóttir H., Robinson J.T., & Mesirov J.P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178-192 (2013
42. Rebouissou S., et al. Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas. Hum. Mol. Genet. 14, 603-614 (2005
43. Trapnell C., et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012
44. Trapnell C., Pachter L., & Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009
45. Katz Y., Wang E.T., Airoldi E.M., & Burge C.B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods 7, 1009-1015 (2010
46. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16, 10881-10890 (1988
47. Tamura K., & Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol. Biol. Evol. 10, 512-526 (1993
48. Tamura K., Stecher G., Peterson D., Filipski A., & Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. 30, 2725-2729 (2013
49. Hope A.C. A simplified Monte Carolo significance test procedure. J. R. Stat. Soc., B 30, 582-598 (1968